Triple negative breast cancer in a male‐to‐female transsexual

Pattison, Sharon; McLaren, Blair

doi:10.1111/imj.12047

Cited by 37 publications

(22 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Transgender individuals should also not exclude surveillance for cancers unique to their natal sex; transgender women have presented with prostate cancer, and transgender men with uterine and cervical cancer [31–33,42]. Both MTF and FTM individuals have presented with breast cancer [34–41].…”

Section: Discussionmentioning

confidence: 99%

Hormone therapy in transgender adults is safe with provider supervision; A review of hormone therapy sequelae for transgender individuals

Weinand

Safer

2015

Journal of Clinical & Translational Endocrinology

105

View full text Add to dashboard Cite

IntroductionSome providers report concern for the safety of transgender hormone therapy (HT).MethodsThis is a systematic literature review of HT safety for transgender adults.ResultsCurrent literature suggests HT is safe when followed carefully for certain risks. The greatest health concern for HT in transgender women is venous thromboembolism. HT among transgender men appears to cause polycythemia. Both groups experienced elevated fasting glucose. There is no increase in cancer prevalence or mortality due to transgender HT.ConclusionAlthough current data support the safety of transgender HT with physician supervision, larger, long-term studies are needed in transgender medicine.

show abstract

Section: Discussionmentioning

confidence: 99%

Hormone therapy in transgender adults is safe with provider supervision; A review of hormone therapy sequelae for transgender individuals

Weinand

Safer

2015

Journal of Clinical & Translational Endocrinology

105

View full text Add to dashboard Cite

show abstract

“…

W735 detected with radiographic screening [2,4,[9][10][11][12][13] (Table 1).We describe two additional cases of breast cancer in MTF transsexuals. One patient had the first, to our knowledge, case of ductal carcinoma in situ in a MTF transsexual detected as calcifications on a screening mammogram.

…”

mentioning

confidence: 88%

Breast Cancer in Male-to-Female Transsexuals: Use of Breast Imaging for Detection

Maglione

Margolies

Jaffer

et al. 2014

American Journal of Roentgenology

View full text Add to dashboard Cite

Breast cancer occurs in male-to-female transsexuals who receive high doses of exogenous estrogen and develop breast tissue histologically identical to that of a biologically female breast. This exposure to estrogen results in increased risk of breast cancer. The first patient described is a male-to-female transsexual with screening-detected ductal carcinoma in situ and a family history of breast cancer. The other patient is a male-to-female transsexual with invasive ductal carcinoma that was occult on diagnostic digital mammographic and ultrasound findings but visualized on digital breast tomosynthesis and breast MR images. The analysis of the eight previously reported cases showed that breast cancer in male-to-female transsexuals occurs at a younger age and is more frequently estrogen receptor negative than breast cancer in others born biologically male. Screening for breast cancer in male-to-female transsexuals should be undertaken for those with additional risk factors (e.g., family history, BRCA2 mutation, Klinefelter syndrome) and should be available to those who desire screening, preferably in a clinical trial.

show abstract

“…The current literature includes 15 reported cases of breast cancer in transwomen who received estrogen therapy (43)(44)(45)(46)(47)(48)(49)(50)(51)(52)(53). Most reported cases were relatively young, with some patients presenting in their early 30s.…”

Section: Possible Effects Of Cross-sex Hormonesmentioning

confidence: 99%

Cancer in Transgender People: Evidence and Methodological Considerations

Braun

Nash

Tangpricha

et al. 2017

Epidemiologic Reviews

165

122

View full text Add to dashboard Cite

Transgender people comprise a diverse group of individuals whose gender identity or expression differs from that originally assigned to them at birth. Some, but not all, transgender people elect to undergo medical gender affirmation, which may include therapy with cross-sex hormones and/or surgical change of the genitalia and other sex characteristics. As cross-sex hormones administered for the purposes of gender affirmation may be delivered at high doses and over a period of decades, the carcinogenicity of hormonal therapy in transgender people is an area of considerable concern. In addition, concerns about cancer risk in transgender patients have been linked to sexually transmitted infections, increased exposure to well-known risk factors such as smoking and alcohol use, and the lack of adequate access to screening. Several publications have identified cancer as an important priority in transgender health research and called for large-scale studies. The goals of this article are to summarize the evidence on factors that may differentially affect cancer risk in transgender people, assess the relevant cancer surveillance and epidemiologic data available to date, and offer an overview of possible methodological considerations for future studies investigating cancer incidence and mortality in this population.

show abstract

Triple negative breast cancer in a male‐to‐female transsexual

Cited by 37 publications

References 20 publications

Hormone therapy in transgender adults is safe with provider supervision; A review of hormone therapy sequelae for transgender individuals

Hormone therapy in transgender adults is safe with provider supervision; A review of hormone therapy sequelae for transgender individuals

Breast Cancer in Male-to-Female Transsexuals: Use of Breast Imaging for Detection

Cancer in Transgender People: Evidence and Methodological Considerations

Contact Info

Product

Resources

About